AlzeCure Pharma has entered an out-licensing and partnership deal with Danish biotech QuantumCell ApS valued at more than $2.2 billion, excluding royalty payments. The deal covers global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including drug candidate ACD856.
Details of the Deal
The Swedish biotech will receive a total upfront payment of $12 million, of which $5 million constitutes a direct investment in AlzeCure. The deal includes development and commercial milestone payments, as well as tiered single-digit to low double-digit royalties on sales.
AlzeCure develops small-molecule drug candidates for central nervous system diseases with a focus on Alzheimer’s disease and pain. The drug candidate, currently in clinical development, helps protect nerve cells from damage, reduces inflammation, and slows or changes the progression of disease.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
